湿性年龄相关性黄斑变性的药物治疗进展

年龄相关性黄斑变性（age-related macular degeneration,AMD）目前已是西方国家首位致盲原因,在我国老年人中也已成为主要的致盲性疾病之一.绝大部分因AMD失明的患者系由于并发脉络膜新生血管（choroidal neovascularization,CNV）.针对新生血管生成的靶向血管内皮生长因子（vascular epithelium growth factor,VEGF）治疗,如雷珠单抗、阿柏西普等大大降低患者的致盲率.此外,随着对新生血管机制研究的进一步深入,一些针对新生血管信号传递多个环节的治疗药物,包括以VEGF为靶点的siRNA、VEGF受体酪氨酸酶抑制剂、补体因子、趋化因子、色素上皮衍生因子、糖皮质激素等将给湿性AMD患者带来新希望.

The update mediction treatment of wet age-related macular degeneration

Age-related macular degeneration （AMD） has now become the leading cause of blindness in western developed countries,and it has also become one of the major blinding diseases in elderly Chinese.The vast majority of AMD patients become blind due to the choroidal neovascularization （CNV）.Targeted anti-VEGF therapy for angiogensis,like ranibizumab and aflibercept can reduce greatly the rate of blindness in AMD patients.In addition,with the further in-depth study of the mechanism of angiogensis,it is expected to develop a number of drugs,including siRNA targeted for VEGF,VEGF receptor tyrosine kinase inhibitor（TKI）,complement factor,chemokines,pigment epithelium-derived factor （PEDF）,steroids,medications targeted for the multiple aspects of the signal pathway in neovascular,which will bring new hope for wet AMD patients.